

BridgeBio Pharma (USA): Merger with Eidos Therapeutics (USA) Changes in Russell Equal Weight Index Series

22 January 2021

Subject to the completion of the merger between BridgeBio Pharma (USA, constituent) and Eidos Therapeutics (USA, constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell 2000 Equal Weight	27 January 2021

*In the absence of an active market, Eidos Therapeutics will be removed at the default merger terms of 1.85 shares of BridgeBio Pharma for each share of Eidos Therapeutics held.

**Based on the default merger terms of 1.85 shares of BridgeBio Pharma per share of Eidos Therapeutics held.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2021 FTSE Russell